Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

KURA
Kura Oncology, Inc.
stock NASDAQ

Market Open
Aug 11, 2026 1:28:23 PM EDT
9.94USD+0.659%(+0.07)282,459
9.93Bid   9.95Ask   0.02Spread
Pre-market
Aug 10, 2026 9:12:30 AM EDT
9.53USD-0.406%(-0.04)0
After-hours
Aug 10, 2026 4:21:30 PM EDT
9.95USD+0.798%(+0.08)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 21, 2022
08:08AM EST  The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective   Benzinga
05:49AM EST  FDA Lifts Partial Hold On Kura Oncology's Early-Stage Leukemia Trial   Benzinga
05:18AM EST  Kura Oncology Receives FDA Authorization To Proceed With Phase 1b Study Of KO-539 In Acute Myeloid Leukemia   Benzinga
Jan 20, 2022
04:01PM EST  FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome   GlobeNewswire Inc
Dec 28, 2021
06:57AM EST  Kura Oncology Granted U.S. Patent #11,207,314 'Methods of treating cancer patients with farnesyltransferase inhibitors'   Benzinga
Dec 16, 2021
09:21AM EST  Kura Oncology Doses First Patient In Phase 1/2 Clinical Trial Of Tipifarnib In Combination With Alpelisib In Head And Neck Squamous Cell Carcinoma   Benzinga
09:16AM EST  Preclinical data suggest HRAS and PI3K are co-dependent oncogenes in HNSCC   GlobeNewswire Inc
Dec 13, 2021
10:31AM EST  Kura Oncology Reports Final Results From Phase 2 Study Of Tipifarnib In T-Cell Lymphoma   Benzinga
10:30AM EST  Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma   GlobeNewswire Inc
07:10AM EST  Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax   Benzinga
07:00AM EST  Kura Oncology Reports Preclinical Data Highlighting Synergistic   GlobeNewswire Inc
Dec 6, 2021
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Nov 30, 2021
07:42PM EST  Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (Kura or the Company) (NASDAQ:KURA). Such investors are advised to contact Robert S. Willoughby atnewaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Nov 26, 2021
08:00AM EST  Credit Suisse Maintains Outperform on Kura Oncology, Lowers Price Target to $21   Benzinga
Nov 24, 2021
08:42PM EST  Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (Kura or the Company) (NASDAQ:KURA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
10:44AM EST  HC Wainwright & Co. Maintains Buy on Kura Oncology, Lowers Price Target to $32   Benzinga
07:32AM EST  The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension   Benzinga
06:47AM EST  Kura Oncology Announces FDA Has Places KOMET-001 Phase 1b Study Of KO-539 On Partial Clinical Hold   Benzinga
06:45AM EST  Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute   GlobeNewswire Inc
Nov 23, 2021
07:30AM EST  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences:   GlobeNewswire Inc
Nov 5, 2021
09:32AM EDT  Kura Oncology Q3 EPS $(0.50) Beats $(0.54) Estimate   Benzinga
Nov 4, 2021
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Nov 2, 2021
07:30AM EDT  Kura Oncology to Participate in Credit Suisse Healthcare Conference   GlobeNewswire Inc
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 28, 2021
07:30AM EDT  Kura Oncology to Report Third Quarter 2021 Financial Results   GlobeNewswire Inc
Oct 18, 2021
07:43AM EDT  Kura Oncology Appoints Teresa Bair As Chief Legal Officer   RTTNews
Sep 7, 2021
07:30AM EDT  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences:   GlobeNewswire Inc
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 6, 2021
10:55AM EDT  Credit Suisse Maintains Outperform on Kura Oncology, Lowers Price Target to $40   Benzinga
10:52AM EDT  Kura Oncology Option Alert: Oct 15 $22.5 Calls at the Ask: 250 @ $1.0 vs 750 OI; Ref=$18.525   Benzinga
04:56AM EDT  SVB Leerink Maintains Outperform on Kura Oncology, Raises Price Target to $41   Benzinga
Aug 5, 2021
04:58PM EDT  Kura Oncology Q2 EPS $(0.51) Misses $(0.49) Estimate   Benzinga
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 4, 2021
07:30AM EDT  Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual   GlobeNewswire Inc
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 29, 2021
07:30AM EDT  Kura Oncology Appoints Helen Collins, M.D. to Board of Directors   GlobeNewswire Inc
Jul 20, 2021
04:29PM EDT  CORRECTION: Kura Sushi USA Ticker Is 'KRUS'   Benzinga
04:00PM EDT  Kura Sushi USA Announces Launch of Proposed Public Offering of Common Stock; No Size Disclosed   Benzinga
Jul 6, 2021
07:37AM EDT  Kura Oncology Announces Clinical Collaboration With Novartis To Evaluate Tipifarnib In Combination With Alpelisib   RTTNews
07:31AM EDT  Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma   Benzinga
07:30AM EDT  Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors   GlobeNewswire Inc
Jun 24, 2021
08:38AM EDT  Kura Oncology Doses First Patient In Phase 1b Expansion Cohorts With Menin Inhibitor KO-539   Benzinga
08:30AM EDT  Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose   GlobeNewswire Inc
Jun 10, 2021
07:30AM EDT  Kura Oncology to Participate in JMP SecuritiesLife   GlobeNewswire Inc
Jun 4, 2021
07:39AM EDT  Kura Oncology Appoints Carol Schafer To Board   RTTNews
07:30AM EDT  Kura Oncology Appoints Carol Schafer toBoard of Directors   GlobeNewswire Inc
May 13, 2021
07:30AM EDT  Kura Oncology to Participate in Cowen Virtual Oncology Innovation   GlobeNewswire Inc
May 6, 2021
04:33PM EDT  Kura Oncology Q1 EPS $(0.46) Misses $(0.42) Estimate   Benzinga
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
Apr 29, 2021
07:30AM EDT  Kura Oncology to Report First Quarter 2021 Financial Results   GlobeNewswire Inc
Mar 22, 2021
04:12PM EDT  Kura Oncology Announces The Publication Of Its Tipifarnib Phase 2 Data In Journal Of Clinical Oncology   Benzinga
04:09PM EDT  Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC   GlobeNewswire Inc
Feb 26, 2021
05:20AM EST  SVB Leerink Maintains Outperform on Kura Oncology, Lowers Price Target to $40   Benzinga
Feb 24, 2021
11:02AM EST  HC Wainwright & Co. Maintains Buy on Kura Oncology, Lowers Price Target to $43   Benzinga
10:05AM EST  Kura Oncology shares were trading higher after the company announced it has received FDA Breakthrough Therapy Designation for Tipifarnib in head and nick squamous cell carcinoma.   Benzinga
09:12AM EST  Kura Oncology Receives FDA Breakthrough Therapy Tag For Tipifarnib In Head & Neck Cancer   Benzinga
07:30AM EST  The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO   Benzinga
07:20AM EST  Kura Oncology Q4 EPS $(0.45), Inline   Benzinga
07:20AM EST  Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations   GlobeNewswire Inc
07:01AM EST  Kura Oncology Receives FDA Breakthrough Therapy Designation For Tipifarnib In Head And Neck Squamous Cell Carcinoma   Benzinga
07:00AM EST  Kura Oncology Receives FDA Breakthrough Therapy Designation for   GlobeNewswire Inc
03:35AM EST  Earnings Scheduled For February 24, 2021   Benzinga
Feb 18, 2021
07:30AM EST  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive officer is scheduled to participate in four upcoming virtual investor conferences:   GlobeNewswire Inc
Feb 17, 2021
07:30AM EST  Kura Oncology to Report Fourth Quarter and Full Year 2020   GlobeNewswire Inc
Jan 11, 2021
02:08PM EST  Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling   Benzinga
Jan 7, 2021
07:30AM EST  Kura Oncology to Participate in H.C. Wainwright BioConnect 2021   GlobeNewswire Inc
Jan 6, 2021
07:30AM EST  Kura Oncology to Present at J.P. Morgan Healthcare Conference   GlobeNewswire Inc
Dec 11, 2020
04:05PM EST  Kura Oncology Announces Closing of Public Offering and Full   GlobeNewswire Inc
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
07:30AM EST  Kura Oncology to Participate in the JMP Securities Hematology Summit   GlobeNewswire Inc
Dec 8, 2020
09:11PM EST  Kura Oncology Prices Underwritten Public Offering Of 8.11 Mln Shares At $37.00/shr   RTTNews
08:22PM EST  Kura Oncology Announces Pricing of $300 Million Public Offering of   GlobeNewswire Inc
09:37AM EST  Kura Oncology shares were trading lower after the company announced a $200 million common stock offering.   Benzinga
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 7, 2020
04:02PM EST  Kura Oncology Announces Commencement of Public Offering of $200M of Common Stock   Benzinga
04:01PM EST  Kura Oncology Announces Commencement of Public Offering of Common   GlobeNewswire Inc
12:52PM EST  Kura Oncology shares are trading higher after the company presented clinical data for its menin inhibitor Saturday.   Benzinga
08:06AM EST  10 Biggest Price Target Changes For Monday   Benzinga
06:59AM EST  HC Wainwright & Co. Maintains Buy on Kura Oncology, Raises Price Target to $45   Benzinga
Dec 5, 2020
01:16PM EST  Kura Oncology Presented First Clinical Data for Menin Inhibitor KO-539 at ASH 2020; Announced Evidence of Biologic Activity Observed in Each Dose-escalation Cohort Treated to Date   Benzinga
12:30PM EST  Evidence of biologic activity observed in each dose-escalation cohort treated to date   GlobeNewswire Inc
Dec 3, 2020
09:56AM EST  Benzinga's Top Upgrades, Downgrades For December 3, 2020   Benzinga
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 24, 2020
07:30AM EST  Kura Oncology to Host Virtual Investor Event on December 5, 2020   GlobeNewswire Inc
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 12, 2020
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 6, 2020
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
Nov 5, 2020
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
07:49AM EST  Kura Oncology Q3 EPS $(0.42) Misses $(0.40) Estimate   Benzinga
07:30AM EST  Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH   GlobeNewswire Inc
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 4, 2020
07:30AM EST  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three upcoming virtual investor conferences:   GlobeNewswire Inc
Nov 2, 2020
08:59AM EST  Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 29, 2020
07:30AM EDT  Kura Oncology to Report Third Quarter 2020 Financial Results   GlobeNewswire Inc
Oct 26, 2020
07:37AM EDT  UPDATE: Kura Reports 'Company plans to conduct a Phase 1/2 proof-of-concept study of tipifarnib in combination with a PI3K inhibitor in relapsed/refractory HNSCC'   Benzinga
07:36AM EDT  UPDATE: Kura Reports 'Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC'   Benzinga
07:36AM EDT  Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3K Inhibitor in Head and Neck Squamous Cell Carcinoma   Benzinga
07:30AM EDT  Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC   GlobeNewswire Inc
Oct 12, 2020
08:22AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:43AM EDT  HC Wainwright & Co. Maintains Buy on Kura Oncology, Raises Price Target to $40   Benzinga
Oct 8, 2020
08:44AM EDT  10 Biggest Price Target Changes For Thursday   Benzinga
07:59AM EDT  Credit Suisse Maintains Outperform on Kura Oncology, Raises Price Target to $43   Benzinga
Oct 7, 2020
07:36AM EDT  Kura Oncology To Present First Clinical Data From KOMET-001 Study On December 5, 2020   RTTNews
07:32AM EDT  Kura Oncology Highlights Abstract Reporting Prelim. Data From KOMET-001, KO-539 Has Been Accepted For Oral Presentation At American Society Of Hematology Dec. 5, 10:30 a.m. EDT; Abstract Will Be Posted On ASH Site Nov. 5 at 9 a.m.   Benzinga
07:30AM EDT  Kura Oncology Announces Preliminary Data for Menin Inhibitor   GlobeNewswire Inc
Sep 8, 2020
07:30AM EDT  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences:   GlobeNewswire Inc
Aug 25, 2020
07:30AM EDT  Kura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer   GlobeNewswire Inc
Aug 6, 2020
04:49PM EDT  Kura Oncology Q2 EPS $(0.40) Beats $(0.42) Estimate   Benzinga
04:36PM EDT  Kura Oncology S-3 Shows Registration For $300M Mixed Securities Shelf Offering   Benzinga
Aug 4, 2020
07:30AM EDT  Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual   GlobeNewswire Inc
Jul 30, 2020
07:30AM EDT  Kura Oncology to Report Second Quarter 2020Financial   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC